AMGEN INC(AMGN)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
AMGEN INC (AMGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMGN at 79.2/100 on a 32-signal composite quality model, placing it at rank #43 of 2,961 stocks — the top 5% of the AI-ranked universe. AMGN scores in the top quartile across revenue scale (95.9), profitability (85.6), balance sheet strength (84.5). Shareholder dilution risk is elevated at 49.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AMGEN INC reports quarterly revenue of $10.1B, net income of $2.4B, an operating margin of 34.9%. Top institutional holders of AMGN by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. AMGN trades on the Nasdaq exchange and files with the SEC under CIK 318154. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AMGEN INC directly from SEC EDGAR.
AI Quality Score
79.2/100
AI Rank
#43
Revenue
$10.1B
Net Income
$2.4B
Free Cash Flow
$3.5B
Operating Margin
34.9%
AMGN key financials by period
AMGEN INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$36.8B
$7.7B
24.7%
FY 2024
10-K
$33.4B
$4.1B
21.7%
FY 2023
10-K
$28.2B
$6.7B
28.0%
FY 2022
10-K
$26.3B
$6.6B
36.3%
FY 2021
10-K
$26.0B
$5.9B
29.4%
FY 2020
10-K
$25.4B
$7.3B
35.9%
Institutions holding AMGN
Institutional investors reporting a position in AMGEN INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Total revenues rose 10% to $10,054M as volume-driven growth in Repatha, EVENITY, UPLIZNA and TEZSPIRE outweighed biosimilar erosion in Prolia and XGEVA; net income rose 66% to $2,375M.
Biggest Revenue Drivers
Product sales$9,537M+9% YoY
Increase driven by volume growth; U.S. volume grew 9% and ROW volume grew 8%
Other revenues$517M+27% YoY
Driven by higher corporate partner revenue and royalty income
Biggest Revenue Drivers
Total revenue: $10,054M+10% YoY
Product sales$9,537M+9% YoY
Increase driven by volume growth; U.S. volume grew 9% and ROW volume grew 8%
Within Product sales
Repatha$953M+37% YoY
Driven by volume growth
Prolia$759M-32% YoY
Lower volume of 20% and lower net selling price of 12% amid multiple biosimilar launches
EVENITY$714M+38% YoY
Driven by volume growth
Other revenues$517M+27% YoY
Driven by higher corporate partner revenue and royalty income
Largest Expense Items
Cost of sales$2,811M-7% YoY
Lower amortization from acquisition-related assets, partly offset by higher profit share expense, manufacturing costs and sales mix
Research and development$1,868M+7% YoY
Higher spend in Later-Stage Clinical Programs, primarily MariTide, and Marketed Product Support
Selling, general and administrative$1,745M+3% YoY
Higher general and administrative expenses and higher commercial product-related expenses
Other operating expenses$116M+51% YoY
Included litigation expenses and settlements
Margins: Cost of sales fell to 28.0% of total revenues from 32.8%, driven by lower acquisition-related amortization, partly offset by higher profit share, manufacturing costs and sales mix; operating income rose 32%.
Watch Items from the Filing
IRS disputes seek additional federal tax of ~$3.6B (2010–2012) and ~$5.1B plus ~$2.0B penalties (2013–2015); a new 2016–2018 NOPA was reissued in July 2026.
FDA proposed withdrawing TAVNEOS approval; related developed-product-technology rights carry $2.4B, with $2.3B tied to the U.S. market.
Prolia fell 32% and XGEVA fell 34%; company expects accelerated erosion for the remainder of 2026 as biosimilars launch in the U.S. and ROW.
ENBREL net selling price fell 22% from U.S. Medicare Part D price setting effective January 1, 2026; Otezla price setting begins January 2027.
BeOne equity stake (~17%) valued at $5.4B produced a $227M unrealized loss in the quarter, recorded in other expense.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
